Christopher Posner
2022
In 2022, Christopher Posner earned a total compensation of $2.5M as President and Chief Executive Officer at Cara Therapeutics, a 75% decrease compared to previous year.
Compensation breakdown
| Bonus | $200,000 |
|---|---|
| Non-Equity Incentive Plan | $294,000 |
| Option Awards | $898,280 |
| Salary | $700,000 |
| Stock Awards | $407,940 |
| Other | $9,759 |
| Total | $2,509,979 |
Posner received $898.3K in option awards, accounting for 36% of the total pay in 2022.
Posner also received $200K in bonus, $294K in non-equity incentive plan, $700K in salary, $407.9K in stock awards and $9.8K in other compensation.
Rankings
In 2022, Christopher Posner's compensation ranked 1,447th out of 5,753 executives tracked by ExecPay. In other words, Posner earned more than 74.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,447 out of 5,753 | 75th |
Division Manufacturing | 722 out of 3,133 | 77th |
Major group Chemicals And Allied Products | 281 out of 1,419 | 80th |
Industry group Drugs | 260 out of 1,320 | 80th |
Industry Pharmaceutical Preparations | 183 out of 966 | 81st |
Source: SEC filing on April 20, 2023.
Posner's colleagues
We found two more compensation records of executives who worked with Christopher Posner at Cara Therapeutics in 2022.